Your browser doesn't support javascript.
loading
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer, Ahmet Z; MacGregor, Gordon; Azevedo, Pilar; Indihar, Veronica; Keating, Claire; Mall, Marcus A; McKone, Edward F; Ramsey, Bonnie W; Rowe, Steven M; Rubenstein, Ronald C; Taylor-Cousar, Jennifer L; Tullis, Elizabeth; Yonker, Lael M; Chu, Chenghao; Lam, Anna P; Nair, Nitin; Sosnay, Patrick R; Tian, Simon; Van Goor, Fredrick; Viswanathan, Lakshmi; Waltz, David; Wang, Linda T; Xi, Yingmei; Billings, Joanne; Horsley, Alexander.
Afiliação
  • Uluer AZ; Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Brigham & Women's Hospital CF Center, Boston, MA, USA.
  • MacGregor G; Queen Elizabeth University Hospital, Glasgow, UK.
  • Azevedo P; Hospital de Santa Maria (CHLN), Lisbon Academic Medical Center, Lisbon, Portugal.
  • Indihar V; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Keating C; Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
  • Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany; Freie Universität Berlin, Berlin, Germany; Humboldt-Universität zu Berlin, Berlin
  • McKone EF; St Vincent's University Hospital, Dublin, Ireland.
  • Ramsey BW; Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Research Institute, Seattle, WA, USA.
  • Rowe SM; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Rubenstein RC; Washington University School of Medicine in St Louis, St Louis, MO, USA.
  • Taylor-Cousar JL; National Jewish Health, Denver, CO, USA.
  • Tullis E; University of Toronto, Toronto, ON, Canada.
  • Yonker LM; Mass General Hospital for Children, Harvard Medical School, Boston, MA, USA.
  • Chu C; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Lam AP; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Nair N; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Sosnay PR; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Tian S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Van Goor F; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Viswanathan L; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Waltz D; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Wang LT; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Xi Y; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Billings J; Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Horsley A; Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester, UK. Electronic address: alexander.horsley@manchester.ac.uk.
Lancet Respir Med ; 11(6): 550-562, 2023 06.
Article em En | MEDLINE | ID: mdl-36842446
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos